The number of years that a patient with right ventricular hypertrophy can generally live is mainly based on the specific etiology, severity of the disease, individual patient condition and other factors, and should be analyzed on a case-by-case basis, and cannot be generalized. If right ventricular hypertrophy is caused by pulmonary artery stenosis or pulmonary artery embolism, patients can generally have a good prognosis and survive for a long time by actively dealing with the primary cause, such as thrombolytic therapy. In case of right ventricular hypertrophy due to hypertrophic cardiomyopathy, patients can only be actively given medication to reduce the occurrence of arrhythmias as well as to reduce the possibility of heart failure and sudden cardiogenic death, and the specific survival time cannot be specified and varies from person to person. Right ventricular hypertrophy due to pulmonary hypertension will improve with oral pulmonary artery pressure-lowering drugs. In the case of right ventricular hypertrophy due to heart failure, the patient’s survival rate can also be improved after active treatment with diuretics, vasodilators, and improved myocardial remodeling to reduce heart failure symptoms. In contrast, once severe heart failure or malignant arrhythmia occurs, patients may suffer sudden cardiac death and lose their lives in a short period of time. Therefore, patients with right ventricular hypertrophy should promptly visit the cardiovascular medicine department of a regular hospital to clarify the cause and then undergo targeted treatment.